Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization
Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...
Company
Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...
Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...
Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand
Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...
GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...
Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies
Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First
Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s...
Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture...
Organon’s Liptruzet Launches in China for Hypercholesterolemia Treatment
US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet...
LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline
LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...
Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device
Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...
Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion
Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...
EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi
Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...
Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...
AstraZeneca Charts Comprehensive Anti-Obesity Strategy with GLP-1 and Amylin Therapies
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has outlined its strategic advancements and future...
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of...
3SBio’s Thrombopoietin Meets Primary Endpoint in Phase III Trial for Chronic Liver Disease Patients
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced the successful conclusion...